NCT03627754 - A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 5, 2018

Primary Completion Date

April 11, 2019

Study Completion Date

April 11, 2019

Conditions

Hepatic Impairment

Interventions

DRUG

Glasdegib 100 mg single oral dose

A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow-up.

Trial Locations (3)

Orlando Clinical Research Center, Orlando

Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Research Pharmacy, Miami

University of Miami Division of Clinical Pharmacology, Miami